BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Brown PM, Drossman DA, Wood AJ, Cline GA, Frazier KS, Jackson JI, Bronner J, Freiman J, Zambrowicz B, Sands A. The tryptophan hydroxylase inhibitor LX1031 shows clinical benefit in patients with nonconstipating irritable bowel syndrome. Gastroenterology. 2011;141:507-516. [PMID: 21684281 DOI: 10.1053/j.gastro.2011.05.005] [Cited by in Crossref: 76] [Cited by in F6Publishing: 65] [Article Influence: 7.6] [Reference Citation Analysis]
Number Citing Articles
1 Bader M. Inhibition of serotonin synthesis: A novel therapeutic paradigm. Pharmacol Ther 2020;205:107423. [PMID: 31629717 DOI: 10.1016/j.pharmthera.2019.107423] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
2 Brommage R, Liu J, Doree D, Yu W, Powell DR, Melissa Yang Q. Adult Tph2 knockout mice without brain serotonin have moderately elevated spine trabecular bone but moderately low cortical bone thickness. Bonekey Rep 2015;4:718. [PMID: 26229596 DOI: 10.1038/bonekey.2015.87] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
3 Jun SE, Kohen R, Cain KC, Jarrett ME, Heitkemper MM. TPH gene polymorphisms are associated with disease perception and quality of life in women with irritable bowel syndrome. Biol Res Nurs 2014;16:95-104. [PMID: 23172723 DOI: 10.1177/1099800412466694] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
4 Gershon MD. 5-Hydroxytryptamine (serotonin) in the gastrointestinal tract. Curr Opin Endocrinol Diabetes Obes. 2013;20:14-21. [PMID: 23222853 DOI: 10.1097/med.0b013e32835bc703] [Cited by in Crossref: 303] [Cited by in F6Publishing: 143] [Article Influence: 37.9] [Reference Citation Analysis]
5 Mousavi T, Nikfar S, Abdollahi M. An update on efficacy and safety considerations for the latest drugs used to treat irritable bowel syndrome. Expert Opin Drug Metab Toxicol 2020;16:583-604. [PMID: 32380874 DOI: 10.1080/17425255.2020.1767067] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 8.0] [Reference Citation Analysis]
6 Kelly RR, McDonald LT, Jensen NR, Sidles SJ, LaRue AC. Impacts of Psychological Stress on Osteoporosis: Clinical Implications and Treatment Interactions. Front Psychiatry 2019;10:200. [PMID: 31024360 DOI: 10.3389/fpsyt.2019.00200] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 12.0] [Reference Citation Analysis]
7 Tack J, Janssen P, Wouters M, Boeckxstaens G. Targeting serotonin synthesis to treat irritable bowel syndrome. Gastroenterology. 2011;141:420-422. [PMID: 21703266 DOI: 10.1053/j.gastro.2011.06.024] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
8 Bailey C, Ruaux C, Stang BV, Valentine BA. Expression of serotonin, chromogranin-A, serotonin receptor-2B, tryptophan hydroxylase-1, and serotonin reuptake transporter in the intestine of dogs with chronic enteropathy. J Vet Diagn Invest 2016;28:271-8. [PMID: 27026108 DOI: 10.1177/1040638715618232] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
9 Petrassi M, Barber R, Be C, Beach S, Cox B, D'Souza AM, Duggan N, Hussey M, Fox R, Hunt P, Jarai G, Kosaka T, Oakley P, Patel V, Press N, Rowlands D, Scheufler C, Schmidt O, Srinivas H, Turner M, Turner R, Westwick J, Wolfreys A, Pathan N, Watson S, Thomas M. Identification of a Novel Allosteric Inhibitory Site on Tryptophan Hydroxylase 1 Enabling Unprecedented Selectivity Over all Related Hydroxylases. Front Pharmacol 2017;8:240. [PMID: 28529483 DOI: 10.3389/fphar.2017.00240] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.5] [Reference Citation Analysis]
10 Molina-Cerrillo J, Alonso-Gordoa T, Martínez-Sáez O, Grande E. Inhibition of Peripheral Synthesis of Serotonin as a New Target in Neuroendocrine Tumors. Oncologist 2016;21:701-7. [PMID: 27107003 DOI: 10.1634/theoncologist.2015-0455] [Cited by in Crossref: 17] [Cited by in F6Publishing: 16] [Article Influence: 3.4] [Reference Citation Analysis]
11 Chojnacki C, Popławski T, Gasiorowska A, Chojnacki J, Blasiak J. Serotonin in the Pathogenesis of Lymphocytic Colitis. J Clin Med 2021;10:E285. [PMID: 33466782 DOI: 10.3390/jcm10020285] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
12 Levin AD, van den Brink GR. Selective inhibition of mucosal serotonin as treatment for IBD? Gut. 2014;63:866-867. [PMID: 23868328 DOI: 10.1136/gutjnl-2013-305283] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
13 Grasberger H, Chang L, Shih W, Presson AP, Sayuk GS, Newberry RD, Karagiannides I, Pothoulakis C, Mayer E, Merchant JL. Identification of a functional TPH1 polymorphism associated with irritable bowel syndrome bowel habit subtypes. Am J Gastroenterol. 2013;108:1766-1774. [PMID: 24060757 DOI: 10.1038/ajg.2013.304] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]
14 Diwakarla S, Fothergill LJ, Fakhry J, Callaghan B, Furness JB. Heterogeneity of enterochromaffin cells within the gastrointestinal tract. Neurogastroenterol Motil. 2017;29:e13101. [PMID: 28485065 DOI: 10.1111/nmo.13101] [Cited by in Crossref: 30] [Cited by in F6Publishing: 19] [Article Influence: 10.0] [Reference Citation Analysis]
15 Peters MA, Walenkamp AM, Kema IP, Meijer C, de Vries EG, Oosting SF. Dopamine and serotonin regulate tumor behavior by affecting angiogenesis. Drug Resist Updat 2014;17:96-104. [PMID: 25269824 DOI: 10.1016/j.drup.2014.09.001] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 4.7] [Reference Citation Analysis]
16 Bischoff SC, Barbara G, Buurman W, Ockhuizen T, Schulzke JD, Serino M, Tilg H, Watson A, Wells JM. Intestinal permeability--a new target for disease prevention and therapy. BMC Gastroenterol. 2014;14:189. [PMID: 25407511 DOI: 10.1186/s12876-014-0189-7] [Cited by in Crossref: 695] [Cited by in F6Publishing: 580] [Article Influence: 99.3] [Reference Citation Analysis]
17 Verhaegh BP, de Vries F, Masclee AA, Keshavarzian A, de Boer A, Souverein PC, Pierik MJ, Jonkers DM. High risk of drug-induced microscopic colitis with concomitant use of NSAIDs and proton pump inhibitors. Aliment Pharmacol Ther 2016;43:1004-13. [PMID: 26956016 DOI: 10.1111/apt.13583] [Cited by in Crossref: 69] [Cited by in F6Publishing: 51] [Article Influence: 13.8] [Reference Citation Analysis]
18 Brommage R, Liu J, Hansen GM, Kirkpatrick LL, Potter DG, Sands AT, Zambrowicz B, Powell DR, Vogel P. High-throughput screening of mouse gene knockouts identifies established and novel skeletal phenotypes. Bone Res 2014;2:14034. [PMID: 26273529 DOI: 10.1038/boneres.2014.34] [Cited by in Crossref: 69] [Cited by in F6Publishing: 58] [Article Influence: 9.9] [Reference Citation Analysis]
19 Keszthelyi D, Troost FJ, Jonkers DM, van Eijk HM, Dekker J, Buurman WA, Masclee AA. Visceral hypersensitivity in irritable bowel syndrome: evidence for involvement of serotonin metabolism--a preliminary study. Neurogastroenterol Motil. 2015;27:1127-1137. [PMID: 26031193 DOI: 10.1111/nmo.12600] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.7] [Reference Citation Analysis]
20 Waløen K, Kleppe R, Martinez A, Haavik J. Tyrosine and tryptophan hydroxylases as therapeutic targets in human disease. Expert Opin Ther Targets 2017;21:167-80. [PMID: 27973928 DOI: 10.1080/14728222.2017.1272581] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 5.4] [Reference Citation Analysis]
21 Lazaraki G, Chatzimavroudis G, Katsinelos P. Recent advances in pharmacological treatment of irritable bowel syndrome. World J Gastroenterol. 2014;20:8867-8885. [PMID: 25083060 DOI: 10.3748/wjg.v20.i27.8867] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
22 Raghupathi R, Duffield MD, Zelkas L, Meedeniya A, Brookes SJ, Sia TC, Wattchow DA, Spencer NJ, Keating DJ. Identification of unique release kinetics of serotonin from guinea-pig and human enterochromaffin cells. J Physiol. 2013;591:5959-5975. [PMID: 24099799 DOI: 10.1113/jphysiol.2013.259796] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 5.9] [Reference Citation Analysis]
23 Sinagra E, Pompei G, Tomasello G, Cappello F, Morreale GC, Amvrosiadis G, Rossi F, Lo Monte AI, Rizzo AG, Raimondo D. Inflammation in irritable bowel syndrome: Myth or new treatment target? World J Gastroenterol. 2016;22:2242-2255. [PMID: 26900287 DOI: 10.3748/wjg.v22.i7.2242] [Cited by in CrossRef: 51] [Cited by in F6Publishing: 42] [Article Influence: 12.8] [Reference Citation Analysis]
24 Dothel G, Barbaro MR, Raschi E, Barbara G, De Ponti F. Advancements in drug development for diarrhea-predominant irritable bowel syndrome. Expert Opin Investig Drugs 2018;27:251-63. [PMID: 29451407 DOI: 10.1080/13543784.2018.1442434] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
25 Lee GS, Simpson C, Sun BH, Yao C, Foer D, Sullivan B, Matthes S, Alenina N, Belsky J, Bader M, Insogna KL. Measurement of plasma, serum, and platelet serotonin in individuals with high bone mass and mutations in LRP5. J Bone Miner Res 2014;29:976-81. [PMID: 24038240 DOI: 10.1002/jbmr.2086] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 3.1] [Reference Citation Analysis]
26 Qin HY, Cheng CW, Tang XD, Bian ZX. Impact of psychological stress on irritable bowel syndrome. World J Gastroenterol. 2014;20:14126-14131. [PMID: 25339801 DOI: 10.3748/wjg.v20.i39.14126] [Cited by in CrossRef: 95] [Cited by in F6Publishing: 79] [Article Influence: 15.8] [Reference Citation Analysis]
27 Smith TK, Gershon MD. Rebuttal from Terence K. Smith and Michael D. Gershon. J Physiol 2015;593:3233. [PMID: 26228549 DOI: 10.1113/JP270683] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
28 Distrutti E, Cipriani S, Mencarelli A, Renga B, Fiorucci S. Probiotics VSL#3 protect against development of visceral pain in murine model of irritable bowel syndrome. PLoS One. 2013;8:e63893. [PMID: 23691109 DOI: 10.1371/journal.pone.0063893] [Cited by in Crossref: 72] [Cited by in F6Publishing: 62] [Article Influence: 9.0] [Reference Citation Analysis]
29 Margolis KG, Stevanovic K, Li Z, Yang QM, Oravecz T, Zambrowicz B, Jhaver KG, Diacou A, Gershon MD. Pharmacological reduction of mucosal but not neuronal serotonin opposes inflammation in mouse intestine. Gut. 2014;63:928-937. [PMID: 23749550 DOI: 10.1136/gutjnl-2013-304901] [Cited by in Crossref: 108] [Cited by in F6Publishing: 95] [Article Influence: 13.5] [Reference Citation Analysis]
30 Manocha M, Khan WI. Serotonin and GI Disorders: An Update on Clinical and Experimental Studies. Clin Transl Gastroenterol. 2012;3:e13. [PMID: 23238212 DOI: 10.1038/ctg.2012.8] [Cited by in Crossref: 105] [Cited by in F6Publishing: 89] [Article Influence: 11.7] [Reference Citation Analysis]
31 Grifka-Walk HM, Jenkins BR, Kominsky DJ. Amino Acid Trp: The Far Out Impacts of Host and Commensal Tryptophan Metabolism. Front Immunol 2021;12:653208. [PMID: 34149693 DOI: 10.3389/fimmu.2021.653208] [Reference Citation Analysis]
32 Matthes S, Bader M. Peripheral Serotonin Synthesis as a New Drug Target. Trends Pharmacol Sci 2018;39:560-72. [PMID: 29628275 DOI: 10.1016/j.tips.2018.03.004] [Cited by in Crossref: 32] [Cited by in F6Publishing: 23] [Article Influence: 10.7] [Reference Citation Analysis]
33 Terry N, Margolis KG. Serotonergic Mechanisms Regulating the GI Tract: Experimental Evidence and Therapeutic Relevance. Handb Exp Pharmacol 2017;239:319-42. [PMID: 28035530 DOI: 10.1007/164_2016_103] [Cited by in Crossref: 36] [Cited by in F6Publishing: 30] [Article Influence: 9.0] [Reference Citation Analysis]
34 Deiana S, Gabbani T, Bagnoli S, Annese V. Emerging drug for diarrhea predominant irritable bowel syndrome. Expert Opin Emerg Drugs 2015;20:247-61. [PMID: 25732091 DOI: 10.1517/14728214.2015.1013935] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
35 Wang C, Fang X. Inflammation and Overlap of Irritable Bowel Syndrome and Functional Dyspepsia. J Neurogastroenterol Motil 2021;27:153-64. [PMID: 33795538 DOI: 10.5056/jnm20175] [Reference Citation Analysis]
36 Barnes NM, Ahern GP, Becamel C, Bockaert J, Camilleri M, Chaumont-Dubel S, Claeysen S, Cunningham KA, Fone KC, Gershon M, Di Giovanni G, Goodfellow NM, Halberstadt AL, Hartley RM, Hassaine G, Herrick-Davis K, Hovius R, Lacivita E, Lambe EK, Leopoldo M, Levy FO, Lummis SCR, Marin P, Maroteaux L, McCreary AC, Nelson DL, Neumaier JF, Newman-Tancredi A, Nury H, Roberts A, Roth BL, Roumier A, Sanger GJ, Teitler M, Sharp T, Villalón CM, Vogel H, Watts SW, Hoyer D. International Union of Basic and Clinical Pharmacology. CX. Classification of Receptors for 5-hydroxytryptamine; Pharmacology and Function. Pharmacol Rev 2021;73:310-520. [PMID: 33370241 DOI: 10.1124/pr.118.015552] [Cited by in Crossref: 25] [Cited by in F6Publishing: 20] [Article Influence: 25.0] [Reference Citation Analysis]
37 Mozaffari S, Nikfar S, Abdollahi M. Metabolic and toxicological considerations for the latest drugs used to treat irritable bowel syndrome. Expert Opin Drug Metab Toxicol. 2013;9:403-421. [PMID: 23330973 DOI: 10.1517/17425255.2013.759558] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
38 Spiller R, Major G. IBS and IBD - separate entities or on a spectrum? Nat Rev Gastroenterol Hepatol. 2016;13:613-621. [PMID: 27667579 DOI: 10.1038/nrgastro.2016.141] [Cited by in Crossref: 70] [Cited by in F6Publishing: 57] [Article Influence: 17.5] [Reference Citation Analysis]
39 Scarpellini E, Laterza L, Ianiro G, Tack J, Abenavoli L, Gasbarrini A. Eluxadoline for the treatment of diarrhoea-predominant irritable bowel syndrome. Expert Opin Pharmacother 2016;17:1395-402. [PMID: 27267380 DOI: 10.1080/14656566.2016.1182982] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
40 Gras B, Magge S, Bloom A, Lembo A. Motility disorders of the colon and rectum. Curr Opin Gastroenterol. 2013;29:66-71. [PMID: 23207598 DOI: 10.1097/mog.0b013e32835a80e7] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
41 Gross Margolis K, Vittorio J, Talavera M, Gluck K, Li Z, Iuga A, Stevanovic K, Saurman V, Israelyan N, Welch MG, Gershon MD. Enteric serotonin and oxytocin: endogenous regulation of severity in a murine model of necrotizing enterocolitis. Am J Physiol Gastrointest Liver Physiol 2017;313:G386-98. [PMID: 28774871 DOI: 10.1152/ajpgi.00215.2017] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
42 Welford RW, Vercauteren M, Trébaul A, Cattaneo C, Eckert D, Garzotti M, Sieber P, Segrestaa J, Studer R, Groenen PM, Nayler O. Serotonin biosynthesis as a predictive marker of serotonin pharmacodynamics and disease-induced dysregulation. Sci Rep 2016;6:30059. [PMID: 27444653 DOI: 10.1038/srep30059] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 5.2] [Reference Citation Analysis]
43 Sinagra E, Morreale GC, Mohammadian G, Fusco G, Guarnotta V, Tomasello G, Cappello F, Rossi F, Amvrosiadis G, Raimondo D. New therapeutic perspectives in irritable bowel syndrome: Targeting low-grade inflammation, immuno-neuroendocrine axis, motility, secretion and beyond. World J Gastroenterol. 2017;23:6593-6627. [PMID: 29085207 DOI: 10.3748/wjg.v23.i36.6593] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 14] [Article Influence: 5.7] [Reference Citation Analysis]
44 Mujagic Z, Keszthelyi D, Aziz Q, Reinisch W, Quetglas EG, De Leonardis F, Segerdahl M, Masclee AA. Systematic review: instruments to assess abdominal pain in irritable bowel syndrome. Aliment Pharmacol Ther 2015;42:1064-81. [PMID: 26290286 DOI: 10.1111/apt.13378] [Cited by in Crossref: 32] [Cited by in F6Publishing: 24] [Article Influence: 5.3] [Reference Citation Analysis]
45 Katsumata R, Shiotani A, Murao T, Ishii M, Fujita M, Matsumoto H, Haruma K. The TPH1 rs211105 gene polymorphism affects abdominal symptoms and quality of life of diarrhea-predominant irritable bowel syndrome. J Clin Biochem Nutr 2018;62:270-6. [PMID: 29892168 DOI: 10.3164/jcbn.17-76] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
46 Linan-Rico A, Ochoa-Cortes F, Beyder A, Soghomonyan S, Zuleta-Alarcon A, Coppola V, Christofi FL. Mechanosensory Signaling in Enterochromaffin Cells and 5-HT Release: Potential Implications for Gut Inflammation. Front Neurosci 2016;10:564. [PMID: 28066160 DOI: 10.3389/fnins.2016.00564] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
47 Zang KH, Shao YY, Zuo X, Rao Z, Qin HY. Oridonin Alleviates Visceral Hyperalgesia in a Rat Model of Postinflammatory Irritable Bowel Syndrome: Role of Colonic Enterochromaffin Cell and Serotonin Availability. J Med Food. 2016;19:586-592. [PMID: 27111743 DOI: 10.1089/jmf.2015.3595] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
48 Wadhwa A, Camilleri M, Grover M. New and Investigational Agents for Irritable Bowel Syndrome. Curr Gastroenterol Rep. 2015;17:46. [PMID: 26446557 DOI: 10.1007/s11894-015-0473-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
49 Camilleri M. Pharmacological agents currently in clinical trials for disorders in neurogastroenterology. J Clin Invest. 2013;123:4111-4120. [PMID: 24084743 DOI: 10.1172/jci70837] [Cited by in Crossref: 24] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
50 Wood JD. Neuropathophysiology of the Irritable Bowel Syndrome. Physiology of the Gastrointestinal Tract. Elsevier; 2018. pp. 1643-68. [DOI: 10.1016/b978-0-12-809954-4.00067-0] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
51 Camilleri M. Current and future pharmacological treatments for diarrhea-predominant irritable bowel syndrome. Expert Opin Pharmacother. 2013;14:1151-1160. [PMID: 23621801 DOI: 10.1517/14656566.2013.794223] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 4.1] [Reference Citation Analysis]
52 Keszthelyi D, Troost F, Simrén M, Ludidi S, Kruimel J, Conchillo J, Masclee A. Revisiting concepts of visceral nociception in irritable bowel syndrome: Visceronociception in irritable bowel syndrome. EJP 2012;16:1444-54. [DOI: 10.1002/j.1532-2149.2012.00147.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 3.7] [Reference Citation Analysis]
53 Gunn D, Garsed K, Lam C, Singh G, Lingaya M, Wahl V, Niesler B, Henry A, Hall IP, Whorwell P, Spiller R. Abnormalities of mucosal serotonin metabolism and 5-HT3 receptor subunit 3C polymorphism in irritable bowel syndrome with diarrhoea predict responsiveness to ondansetron. Aliment Pharmacol Ther. 2019;50:538-546. [PMID: 31342534 DOI: 10.1111/apt.15420] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
54 Garsed K, Chernova J, Hastings M, Lam C, Marciani L, Singh G, Henry A, Hall I, Whorwell P, Spiller R. A randomised trial of ondansetron for the treatment of irritable bowel syndrome with diarrhoea. Gut. 2014;63:1617-1625. [PMID: 24334242 DOI: 10.1136/gutjnl-2013-305989] [Cited by in Crossref: 121] [Cited by in F6Publishing: 100] [Article Influence: 15.1] [Reference Citation Analysis]
55 Shiotani A, Kusunoki H, Ishii M, Imamura H, Manabe N, Kamada T, Hata J, Merchant JL, Haruma K. Pilot study of Biomarkers for predicting effectiveness of ramosetron in diarrhea-predominant irritable bowel syndrome: expression of S100A10 and polymorphisms of TPH1. Neurogastroenterol Motil 2015;27:82-91. [PMID: 25428414 DOI: 10.1111/nmo.12473] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
56 Simrén M, Tack J. New treatments and therapeutic targets for IBS and other functional bowel disorders. Nat Rev Gastroenterol Hepatol 2018;15:589-605. [PMID: 29930260 DOI: 10.1038/s41575-018-0034-5] [Cited by in Crossref: 51] [Cited by in F6Publishing: 40] [Article Influence: 25.5] [Reference Citation Analysis]
57 Jing F, Zhang J. Metabolic kinetics of 5-hydroxytryptamine and the research targets of functional gastrointestinal disorders. Dig Dis Sci. 2014;59:2642-2648. [PMID: 24916714 DOI: 10.1007/s10620-014-3244-x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
58 Mawe GM, Hoffman JM. Serotonin signalling in the gut--functions, dysfunctions and therapeutic targets. Nat Rev Gastroenterol Hepatol. 2013;10:473-486. [PMID: 23797870 DOI: 10.1038/nrgastro.2013.105] [Cited by in Crossref: 452] [Cited by in F6Publishing: 381] [Article Influence: 56.5] [Reference Citation Analysis]
59 Spiller R, Lam C. An Update on Post-infectious Irritable Bowel Syndrome: Role of Genetics, Immune Activation, Serotonin and Altered Microbiome. J Neurogastroenterol Motil. 2012;18:258-268. [PMID: 22837873 DOI: 10.5056/jnm.2012.18.3.258] [Cited by in Crossref: 98] [Cited by in F6Publishing: 87] [Article Influence: 10.9] [Reference Citation Analysis]
60 Brommage R, Powell DR, Vogel P. Predicting human disease mutations and identifying drug targets from mouse gene knockout phenotyping campaigns. Dis Model Mech 2019;12:dmm038224. [PMID: 31064765 DOI: 10.1242/dmm.038224] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
61 Voß U, Lewerenz A, Nieber K. Treatment of irritable bowel syndrome: sex and gender specific aspects. Handb Exp Pharmacol. 2012;473-497. [PMID: 23027463 DOI: 10.1007/978-3-642-30726-3_21] [Cited by in Crossref: 10] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
62 Thiagarajah JR, Donowitz M, Verkman AS. Secretory diarrhoea: mechanisms and emerging therapies. Nat Rev Gastroenterol Hepatol. 2015;12:446-457. [PMID: 26122478 DOI: 10.1038/nrgastro.2015.111] [Cited by in Crossref: 86] [Cited by in F6Publishing: 67] [Article Influence: 14.3] [Reference Citation Analysis]
63 Vanuytsel T, Tack JF, Boeckxstaens GE. Treatment of abdominal pain in irritable bowel syndrome. J Gastroenterol. 2014;49:1193-1205. [PMID: 24845149 DOI: 10.1007/s00535-014-0966-7] [Cited by in Crossref: 33] [Cited by in F6Publishing: 21] [Article Influence: 4.7] [Reference Citation Analysis]
64 Spiller R, Lam C. An Update on Post-infectious Irritable Bowel Syndrome: Role of Genetics, Immune Activation, Serotonin and Altered Microbiome. J Neurogastroenterol Motil. 2012;18:258-268. [PMID: 22837873 DOI: 10.5056/jnm.2012. 18.3.258] [Reference Citation Analysis]
65 Camilleri M, Bueno L, Andresen V, De Ponti F, Choi MG, Lembo A. Pharmacological, Pharmacokinetic, and Pharmacogenomic Aspects of Functional Gastrointestinal Disorders. Gastroenterology. 2016; Epub ahead of print. [PMID: 27144621 DOI: 10.1053/j.gastro.2016.02.029] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]